Acrux gains FDA approval for new product

Acrux (ASX:ACR), a specialty pharmaceuticals company, announced FDA approval for its Dapsone 7.5% Gel. The product is set for launch in early 2025. This follows the launch of Dapsone 5% Gel earlier in 2024. Acrux aims to expand its product offerings to support sustainable revenue growth.

Acrux's growth strategy and future outlook

Acrux is focused on enhancing its revenue growth through new product launches. With the recent FDA approval of Dapsone 7.5% Gel, the company targets a launch in early 2025. Acrux plans to introduce another product by the end of Q1 2025. The company is working to expand its portfolio of topically applied pharmaceutical products in the U.S. market. Financially, Acrux reported net cash outflows and utilized an R&D Tax Incentive rebate to manage cash flow. Looking ahead, Acrux aims to sustain growth by leveraging new product launches to increase market penetration and revenue streams.

Executive insights on Acrux's strategic direction

The approval of Dapsone 7.5% Gel marks a significant milestone. We are committed to expanding our portfolio to ensure sustainable growth,' noted the company's executive team.